Antibody persistence following MeNZB vaccination of adults and children and response to a fourth dose in toddlers

Archives of Disease in Childhood

Volumn 96, Issue 8, 2011, Pages 744-751

  Jackson, Catherine ^a   Lennon, Diana ^a   Wong, Sharon ^a   Yan, Jacqueline ^a   Stewart, Joanna ^a   Reid, Stewart ^b   Oster, Philipp ^c   Ypma, Ellen ^c   Martin, Diana ^d  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b Ropata Medical Centre   (New Zealand)

^c NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^d INSTITUTE OF ENVIRONMENTAL SCIENCE AND RESEARCH   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; MENINGOCOCCUS VACCINE;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BACTERICIDAL ACTIVITY; CHILD; DRUG SAFETY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; MALE; NEISSERIA MENINGITIDIS; NORMAL HUMAN; PRIORITY JOURNAL; SCHOOL CHILD; TODDLER; VACCINATION;

ADULT; AGE FACTORS; ANTIBODIES, BACTERIAL; BLOOD BACTERICIDAL ACTIVITY; CHILD; DISEASE OUTBREAKS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; INFANT; MALE; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; NEW ZEALAND;

EID: 79960554584     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2009.180596     Document Type: Article

References (41)

1. Martin DR, Walker SJ, Baker MG, et al. New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4. J Infect Dis 1998;177:497-500. (Pubitemid 28063785)
2. Thornton V, Lennon D, Rasanathan K, et al. Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control. Vaccine 2006;24:1395-400. (Pubitemid 43222049)
3. Wong S, Lennon D, Jackson C, et al. New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months. Pediatr Infect Dis J 2007;26:345-50. (Pubitemid 46596661)
4. Hosking J, Rasanathan K, Mow FC, et al. Immunogenicity, reactogenicity, and safety of a P1.7b,4 strain-specific serogroup B meningococcal vaccine given to preteens. Clin Vaccine Immunol 2007;14:1393-9. (Pubitemid 350304030)
5. Jackson C, Lennon DR, Sotutu VT, et al. Phase II meningococcal B vesicle vaccine trial in New Zealand infants. Arch Dis Child 2009;94:745-51.
6. Wong SH, Lennon DR, Jackson CM, et al. Immunogenicity and tolerability in infants of a New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine. Pediatr Infect Dis J 2009;28:385-90.
7. de Moraes J C, Perkins BA, Camargo MC, et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 1992;340:1074-8.
8. Sotolongo F, Casanueva GV, Fajardo E, et al. Cuban meningococcal BC vaccine: experiences and contributions from 20 years of application. MEDICC Rev 2007;9:16-22.
9. Martin D, McDowell R,. The Epidemiology of Meningococcal Disease in New Zealand in 2003. Report Prepared for the Ministry of Health by the Institute of Environmental Science and Research Limited (ESR). Wellington: Ministry of Health, 2004.
10. Martin D, Lopez L. The Epidemiology of Meningococcal Disease in New Zealand in 2009. Wellington: Ministry of Health, 2010.
11. Lennon D, Jackson C, Wong S, et al. Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand. Clin Infect Dis 2009;49:597-605.
12. Rosenqvist E, Høiby EA, Wedege E, et al. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect Immun 1995;63:4642-52.
13. de Kleijn ED, de Groot R, Lafeber AB, et al. Immunogenicity and safety of monovalent p1.7(h),4 meningococcal outer membrane vesicle vaccine in toddlers: comparison of two vaccination schedules and two vaccine formulations. Vaccine 2000;19:1141-8. (Pubitemid 32008280)
14. Martin D, McCallum L, Glennie A, et al. Validation of the serum bactericidal assay for measurement of functional antibodies against group B meningococci associated with vaccine trials. Vaccine 2005;23:2218-21. (Pubitemid 40341455)
15. Agresti A, Coull B. Approximation is better than 'exact' for interval estimation of binomial proportions. Am Stat 1998;52:119-26.
16. Perkins B A, Jonsdottir K, Briem H, et al. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J Infect Dis 1998;177:683-91. (Pubitemid 28099883)
17. Feiring B, Fuglesang J, Oster P, et al. Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine. Clin Vaccine Immunol 2006;13:790-6.
18. Martin D, Wong S, O'Hallahan J, et al. How do we determine a biologically meaningful protective level? Proceeding of 15th International Pathogenic Neisseria Conference 2006 (Abstract S13.2), 10-15 September, 2006, Cairns, Queensland, Australia.
19. Sandbu S, Feiring B, Oster P, et al. Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines. Clin Vaccine Immunol 2007;14:1062-9. (Pubitemid 47518071)
20. Ruijne N, Lea RA, O'Hallahan J, et al. Understanding the immune responses to the meningococcal strain-specific vaccine MeNZB measured in studies of infants. Clin Vaccine Immunol 2006;13:797-801.
21. Snape MD, Kelly DF, Salt P, et al. Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization. Clin Infect Dis 2006;43:1387-94. (Pubitemid 44845637)
22. Borrow R, Aaberge IS, Santos GF, et al. Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine. Clin Diagn Lab Immunol 2005;12:970-6.
23. Holst J, Feiring B, Fuglesang JE, et al. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine 2003;21:734-7. (Pubitemid 36091989)
24. Granoff DM. Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease. Vaccine 2009;27(Suppl 2):B117-25.
25. Findlow J, Taylor S, Aase A, et al. Comparison and correlation of neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac. Infect Immun 2006;74:4557-65. (Pubitemid 44157242)
26. Frasch CE, Borrow R, Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 2009;27(Suppl 2):B112-16.
27. Milagres LG, Ramos SR, Sacchi CT, et al. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect Immun 1994;62:4419-24.
28. Galloway Y, Stehr-Green P, McNicholas A, et al. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. Int J Epidemiol 2009;38:413-18.
29. McNicholas A, Galloway Y, Martin D, et al. Surveillance of vaccine breakthrough cases following MeNZB vaccination. N Z Med J 2008;121:38-46.
30. Kelly C, Arnold R, Galloway Y, et al. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Am J Epidemiol 2007;166:817-23. (Pubitemid 47428901)
31. Trotter CL, Andrews NJ, Kaczmarski EB, et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004;364:365-7. (Pubitemid 38970013)
32. Larrauri A, Cano R, García M, et al. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine 2005;23:4097-100. (Pubitemid 40814584)
33. Perrett KP, Winter AP, Kibwana E, et al. Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial. Clin Infect Dis 2010;50:1601-10.
34. Diez-Domingo J, Planelles-Cantarino MV, Baldo-Torrenti JM, et al. Antibody persistence 12 months after a booster dose of meningococcal-C conjugated vaccine in the second year of life. Pediatr Infect Dis J 2010;29:768-70.
35. Heath PT, Booy R, Azzopardi HJ, et al. Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdom. JAMA 2000;284:2334-40.
36. Harrison LH. Vaccine prevention of meningococcal disease: making slow progress. Clin Infect Dis 2006;43:1395-7. (Pubitemid 44845638)
37. Auckland C, Gray S, Borrow R, et al. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis 2006;194:1745-52. (Pubitemid 44902007)
38. Campbell H, Andrews N, Borrow R, et al. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol 2010;17:840-7.
39. Borrow R, Andrews N, Findlow H, et al. Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine. Clin Vaccine Immunol 2010;17:154-9.
40. Findlow J, Borrow R, Snape MD, et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 2010;51:1127-37.
41. Holst J. Strategies for development of universal vaccines against meningococcal serogroup B disease: the most promising options and the challenges evaluating them. Hum Vaccin 2007;3:290-4.